Market Overview The bone metastasis market is entering a new era as immunotherapy combinations demonstrate efficacy against skeletal lesions previously considered resistant to immune-based approaches. The bone microenvironment creates immunosuppressive conditions through myeloid-derived suppressor cells, regulatory T cells, and altered cytokine profiles that shield metastatic cells from immune...